PUBLIC COMPANY
save$PGENPRECIGEN, INC.
$PGEN8.5600+6.34%Germantown, MD, USupdated 11h ago
Precigen, Inc. is an American biotechnology company. Its president and CEO is Helen Sabzevari.
community read0 votes
pipeline
3
marketed
1
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Phase 11Phase 21Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
view all catalysts →Active trials
- phase2PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
- phase4Zopa Retreatment and Vector Shedding in Adults With RRP
- phase2Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis
- phase1PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS
- phase1Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Insider activity
source: SEC Form 4routine RSU / option mechanics (6)
- Apr 20, 26grantLehr Donald P. · Chief Legal Officer358,000 sh
- Apr 20, 26grantLehr Donald P. · Chief Legal Officer107,000 sh
- Apr 20, 26grantSabzevari Helen · President and CEO1,366,000 sh
- Apr 20, 26grantSabzevari Helen · President and CEO410,000 sh
- Apr 20, 26grantShah Rutul R · Chief Operating Officer395,000 sh
- Apr 20, 26grantShah Rutul R · Chief Operating Officer118,000 sh
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 58m ago
Found something off?
comments(0)
5-min edit window · permanent after that